- Tilray Medical, a division of Tilray Brands (TSX,NASDAQ:TLRY), is adding new cannabis extract products to its German medical portfolio
- Additions include a high-dose balanced formulation and a trial-size formulation to better meet the needs of patients and physicians
- Tilray is a global lifestyle and consumer packaged goods company focused on cannabis, beverages, wellness and entertainment
- Tilray stock has given back 45.10 per cent year-over-year and 92.88 per cent since 2021
Tilray Medical, a division of Tilray Brands (TSX,NASDAQ:TLRY), is adding new cannabis extract products to its German medical portfolio. Additions include:
- Tilray THC50 CBD50 (25 ml): A high-potency and balanced medical cannabis extract for those looking for a stronger therapeutic effect tempered by CBD. According to Tuesday’s news release, balanced extracts are one of the most prescribed in Germany.
- Tilray THC10…
